Companies / BMY vs REGN
BMY vs REGN: Bristol Myers Squibb and Regeneron Pharmaceuticals
Bristol Myers Squibb (BMY) reported $48.2B in revenue against a 14.6% net margin, while Regeneron Pharmaceuticals (REGN) reported $14.3B at a 31.4% net margin, most recently.
| Metric | BMY | REGN |
|---|---|---|
| Revenue | $48.2B | $14.3B |
| Net Income | $7.1B | $4.5B |
| Gross Margin | 71.1% | — |
| Operating Margin | 19.4% | 24.9% |
| EPS (Diluted) | $3.46 | $41.48 |
| Free Cash Flow | $12.8B | $4.1B |
| Total Debt | $47.1B | $2.7B |
| P/E Ratio | 15.6× | 18.6× |
| P/B Ratio | n/m | n/m |
| Stock Price | $63.16 | $910.75 |
Free: last 5 years
| Fiscal year | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| REGN Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |